Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Manage your formulary budget
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Implantable polymeric device for sustained release of buprenorphine|
|Abstract:||The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.|
|Inventor(s):||Patel; Rajesh A. (Redwood City, CA), Bucalo; Louis R. (Miami Beach, FL)|
|Assignee:||Titan Pharmaceuticals, Inc. (South San Francisco, CA)|
1. A method for treating opiate addiction in a human in need thereof, comprising subcutaneously implanting at least one implantable device comprising buprenorphine and ethylene vinyl
acetate copolymer (EVA), wherein said device comprises a polymeric matrix comprising buprenorphine blended with said EVA copolymer, wherein said buprenorphine is continuously released in vivo over a sustained period of time through pores that open to the
surface of said matrix at a rate that results in a steady state plasma buprenorphine level for at least about 3 months, wherein said device does not comprise a coating that is impermeable to buprenorphine, wherein said device does not comprise external
medical equipment, and wherein said at least one device releases buprenorphine at a rate that results in a therapeutically effective steady state plasma level of about 0.1 ng/ml to about 1 ng/ml to a human in need of treatment for opiate addiction.
2. A method according to claim 1, wherein said EVA comprises about 33% vinyl acetate.
3. A method according to claim 2, wherein said implantable device comprises about 10% to about 85% buprenorphine.
4. A method according to claim 3, wherein said implantable device comprises about 50% buprenorphine.
5. A method according to claim 3, wherein said implantable device comprises about 75% buprenorphine.
6. A method according to claim 2, wherein the implantable device is produced by an extrusion process.
7. A method according to claim 6, wherein the implantable device comprises dimensions of about 1.5 to about 5 mm in diameter and about 0.5 to about 7 cm in length.
8. The method of claim 1, wherein said device is washed with ethanol prior to subcutaneous implantation.
9. The method of claim 8, wherein said washing with ethanol removes surface buprenorphine and reduces the initial burst of buprenorphine released in vivo after subcutaneous implantation relative to an unwashed device.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.